XLON
IDHC
Market cap303mUSD
Oct 09, Last price
0.53USD
1D
0.19%
1Q
3.14%
Jan 2017
-37.61%
IPO
-63.72%
Name
Integrated Diagnostics Holdings PLC
Chart & performance
P/E
12.68
P/S
2.04
EPS
2.17
Div yield, %
3.26%
Shrs. gr., 5y
-0.63%
Rev. gr., 5y
24.22%
Revenues
7.86b
+37.34%
Net income
1.26b
+17.15%
CFO
1.90b
+21.41%
Dividend
May 28, 20260.0085 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Integrated Diagnostics Holdings plc (IDGXF) functions as a consumer-focused healthcare enterprise, primarily dedicated to providing a comprehensive array of medical diagnostic services for patients. Its extensive service portfolio encompasses approximately 2,000 distinct diagnostic examinations, spanning diverse fields such as immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company maintains an operational footprint across Egypt, Jordan, Sudan, and Nigeria. By December 30, 2021, its network had grown to encompass 452 branch laboratories. Established in 1979, the organization's main office is situated in Saint Helier, Jersey.
Key people
Non-Executive Independent Chairman · since 2015
Hend El Sherbini
Group Chief Executive Officer, Executive Director · since 2014
Group Chief Financial Officer, Vice President, Executive Director · since 2024
Non-Executive Director · since 2014
Non-Executive Independent Director · since 2015
Non-Executive Independent Director · since 2015
Non-Executive Independent Director · since 2022
Headquarters & legal address
C/O APEX FINANCIAL SERVICES (TRUSTEES) LIMITED
IFC 5
ST HELIER JE1 1ST
JE
IFC 5
ST HELIER JE1 1ST
JE
Trading name
IDH
Previous name
INTEGRATED DIAGNOSTICS HOLDINGS LIMITED
Valuation
Title EGP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||